The core mechanism of octreotide acetate solution is to inhibit adenylate cyclase activity, reduce intracellular adenosine monophosphate levels, thereby blocking hormone synthesis and release, while regulating vascular function and cell proliferation. This drug is mainly suitable for the following clinical scenarios: emergency treatment of esophageal gastric variceal bleeding caused by cirrhosis, reducing visceral blood flow to lower portal vein pressure, and significantly reducing the rate of rebleeding when combined with endoscopic therapy; Prevent postoperative complications such as pancreati fistula and infection by inhibiting pancreati enzyme secretion; Relieve symptoms related to gastrointetinal and pancreati endocrine tumors, including flushing and diarrhea of carcinoid syndrome and refractory ulcers of gastrinoma, by inhibiting tumor secretion hormons; Control symptoms of acromegaly, reduce levels of growth hormon and insulin-like growth factor-1, and improve symptoms such as headache and joint pain.
Octreotide Acetate COA
Octreotide acetate solution is an artificially synthesized octapeptide compound, which is an analog of tetradecyl peptide human somatotatin. Its mechanism of action simulates the function of natural somatotatin, and after binding to specific receptors, it has a wide range of regulatory effects on multi system hormon exudation, vascular function, and cell proliferation.
Core mechanism of action: regulation of receptor-mediated signaling pathways
Oxtreotide activates intracellular signaling pathways, inhibits adenylate cyclase activity, reduces intracellular cyclic adenosine monophosphate (cAMP) levels, and blocks hormon synthesis and release by binding with high affinity to somatotatin receptor (SSTR) subtypes (mainly SSTR2, SSTR5). This mechanism plays a central role in the following key physiological processes:
Hormone secretion inhibition
Growth hormon (GH) regulation: In the treatment of acromegaly, oxtreotide inhibits GH exudation in the anterior pituitary gland, reduces serum insulin-like growth factor-1 (IGF-1) levels, and alleviates symptoms of headache, joint pain, and soft tissue hyperplasia. Clinical studies have shown that long-term medication can reduce GH levels in 60% -70% of patients to the normal range.
Pancreati endocrine regulation: inhibits glucagon exudation and reduces hepatic glucose output; Simultaneously regulating insulin exudation rhythm, improving insulin resistance, and assisting in controlling blood glucose fluctuations.
Efficiency leap Precision and stability
For patients with insulinoma, it can effectively inhibit hypoglycemic episodes and improve blood glucose stability.
Gut hormon inhibition: By blocking the exudation of vasoactive gut peptide (VIP), gastrin, pancreati secretin, etc., it reduces diarrhea caused by excessive gut exudation. For example, in VIP tumor treatment, the frequency of diarrhea in patients can be reduced from more than 10 times a day to less than 3 times a day.
Vascular function regulation
Changes in visceral hemodynamics: Activation of vascular smooth muscle SSTR2 receptors, induction of calcium ion influx, and triggering vascular constriction. In the treatment of portal hypertension in cirrhosis, portal vein pressure can be reduced by 20% -30%, reducing the risk of esophageal and gastric variceal bleeding. When combined with endoscopic treatment, the rebleeding rate can be reduced from 40% to below 10%.
Control of collateral circulation blood flow: By reducing the blood flow of collateral vessels in the portal vein system, lowering the pressure gradient of varicose veins, and preventing bleeding recurrence.
Cell proliferation inhibition
Antitumor effect: directly inhibits the proliferation of gastrointetinal pancreati neuroendocrine tumor (GEP NETs) cells, induces cell cycle arrest in G1 phase; At the same time, by inhibiting the exudation of vascular endothelial growth factor (VEGF), tumor angiogenesis is reduced. Clinical data shows that patients treated with oxtreotide microspheres can extend their tumor progression free survival to 24-36 months.
Immune regulation: Downregulate the expression of pro-inflammatory cytokines (such as IL-6 and TNF - α), alleviate symptoms of flushing and wheezing related to carcinoid syndrome, and improve the quality of life of patients.
Analysis of target organ specific effects
The action of octreotide acetate solution has organ selectivity, and its strength of effect is closely related to the distribution density of receptors:
Anterior pituitary gland
Prioritize binding to SSTR5 receptors, inhibit GH pulsatile exudation, but have little effect on thyroid stimulating hormon (TSH) exudation. Hypothyroidism may occur in the early stages of treatment (with an incidence rate of about 15%), and TSH levels need to be monitored regularly.
Pancreas
Simultaneously acting on SSTR2 and SSTR5 receptors, inhibiting pancreati enzyme exudation by 70% -80% and reducing acute pancreatitis inflammation. For patients with chronic pancreatitis, it can alleviate abdominal pain symptoms and reduce the progression of exocrine dysfunction.
Gastrointetinal tract
Inhibit gastric emptying (delayed by 2-3 hours) and gut peristalsis, prolonging food passage time. This effect is particularly important in the treatment of dumping syndrome, as it can significantly reduce postprandial hypoglycemia and diarrhea episodes.
Gallbladder
Stimulate the release of cholecystokinin (CCK), promote gallbladder emptying, and reduce the risk of bile stasis. However, long-term use may increase the formation rate of gallstones (about 10% -15%), and regular ultrasound monitoring is necessary.
Verification of the correlation between clinical application and mechanism of action
The multi-target effect of oxtreotide gives it unique advantages in the treatment of the following diseases:
Acromegaly
Mechanism verification: By continuously inhibiting GH exudation, we block IGF-1 mediated bone overgrowth and soft tissue proliferation. Long acting oxtreotide microspheres (LAR) injected once a month can reduce GH levels to<2.5 μ g/L and restore IGF-1 to normal range in 80% of patients.
Gastrointetinal pancreati neuroendocrine tumors
Mechanism verification: Double inhibition of hormon exudation (such as 5-HT, gastrin) and tumor proliferation, alleviating symptoms of carcinoid syndrome. Prior to PRRT (peptide receptor radionuclide therapy), the use of oxtreotide can upregulate tumor SSTR expression and enhance radiotherapy sensitivity.
Acute esophageal and gastric variceal bleeding
Mechanism validation: Quickly reduce portal vein pressure (effective within 15 minutes) to buy time for endoscopic treatment. When combined with vasoactive drugs such as terlipressin, the success rate of hemostasis is increased to over 90%.
Prevention of postoperative complications in pancreati surgery
Mechanism verification: Inhibit pancreati enzyme exudation and reduce the incidence of pancreati fistula (from 15% to below 5%); Simultaneously reducing pancreati parenchymal inflammation and shortening hospitalization time.
Pharmacological action
Oxtreotide has various important pharmacological effects, which are the basis for its therapeutic efficacy.
It can inhibit the pathological overproduction of growth hormon, thyroid stimulating hormon, gastrointetinal and pancreati endocrine hormons. For example, in patients with acromegaly, pituitary tumors can lead to excessive exudation of growth hormon, causing abnormal proliferation of bones and soft tissues. Octreotide acetate solution effectively alleviates symptoms by inhibiting the exudation of growth hormon. In the treatment of gastrointetinal and pancreati endocrine tumors, patients often experience abnormal hormon exudation, leading to symptoms such as diarrhea, flushing, and hypoglycemia. This drug can regulate hormon exudation and improve the condition.
Can selectively reduce the blood flow and pressure of the portal vein and its collateral circulation, and lower the pressure of esophageal and gastric varices. This is crucial for the treatment of esophageal gastric variceal bleeding caused by cirrhosis, as it can reduce the risk of bleeding and buy time for subsequent treatment.
Inhibits gallbladder emptying and has therapeutic effects on pancreati lesions. In the treatment of pancreatitis, oxtreotide can inhibit the exudation of gastric acid, trypsin, glucagon, and insulin, reduce gastric motility and gallbladder emptying, inhibit the exudation of cholecystokinin and glucagon, reduce pancreati exudation, and have a direct protective effect on pancreati parenchymal cell membrane. At the same time, it can also reduce visceral blood flow, lower portal pressure, decrease excessive gut exudation, and increase gut absorption of water and sodium.
Adverse reactions
The use of oxtreotide injection may result in various adverse reactions, mainly including the following categories:
Including anorexia, nausea, vomiting, diarrhea, abdominal spasms and pain, bloating, etc. Although the measured fecal fat excretion may increase, there is no evidence to suggest that long-term treatment with oxtreotide can cause malabsorption and malnutrition. In rare cases, gastrointetinal adverse reactions can be similar to acute gut obstruction accompanied by progressive severe upper abdominal pain, abdominal tenderness, muscle tension, and bloating. Eating should be avoided before and after administration (i.e. injection between meals or during bedroom rest), which can reduce the occurrence of gastrointetinal adverse reactions.
Local reactions:
Pain or tingling sensation at the injection site is common and can generally be relieved after 15 minutes. Skin symptoms such as redness, swelling, skin bruising, urticaria, and even cellulitis may occur. If the medication is allowed to reach room temperature before injection or the concentration of the medication is increased by reducing the amount of solvent, local discomfort can be reduced.
Due to the inhibition of growth hormon, glucagon, and insulin exudation by oxtreotide, it may cause disturbances in blood glucose regulation. It can reduce postprandial glucose tolerance in patients, and some long-term drug users can cause persistent hyperglycemia. Hypoglycemia has also been observed. For patients with insulinoma, this product may worsen the degree of hypoglycemia and prolong its duration, and should be observed carefully.
Other adverse reactions:
Long term use of octreotide acetate solution may lead to the formation of gallstones, with a few reports of acute pancreatitis, but it usually appears within a few hours or days of starting treatment and gradually disappears after discontinuation. Long term use may also lead to gallstones and pancreatitis. Individual patients experience liver dysfunction, including acute hepatitis without bile stasis, and after discontinuation, transaminase levels return to normal; Slow onset hyperbilirubinemia accompanied by elevated alkaline phosphatase, gamma glutamyltransferase, and mild elevation of transaminases.
Hot Tags: octreotide acetate solution, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale